《乙肝治疗策略.ppt》由会员分享，可在线阅读，更多相关《乙肝治疗策略.ppt（52页珍藏版）》请在第壹文秘上搜索。
1、Some of the information without approval 1Some of the information without approval 21.Torresi et al.，Antiviral Chemotherapy for the reatment of Hepatitis B Virus Infections；Gastroenterology.2000;118:S83S1032.Perrillo et al.，Occurrence of Hepatocellular Carcinoma and Decompensation in Western Europea
2、nPatients With Cirrhosis Type B；Hepatology 2001;33:424432肝癌肝癌 (HCC)(HCC)肝硬化肝硬化肝功能衰竭肝功能衰竭慢性乙肝慢性乙肝肝移植肝移植30%30%1 15%-10%5%-10%1 123%23%在确诊肝硬在确诊肝硬化后化后5 5年内年内2 2急性恶化急性恶化Some of the information without approval 3Some of the information without approval 4慢性乙型肝炎防治指南 Chinese Hepatology,Dec 2005,Vol 10,No.4：3
3、48357慢性慢性HBVHBV携带者携带者慢性乙型肝炎慢性乙型肝炎（HBeAg+/-)HBeAg+/-)非活动性非活动性HBsAgHBsAg携携带者带者HBsAgHBsAg+HBeAgHBeAg+/-+/-+/-+/-HBeAbHBeAb-/+-/+-/+-/+ALTALT正常正常异常异常正常正常HBV DNA HBV DNA*（拷贝（拷贝/mL)/mL)肝组织学肝组织学正常正常/轻度异常轻度异常不同程度异常不同程度异常正常正常/轻度异常轻度异常*PCRPCR检测方法检测方法Some of the information without approval 5慢性乙型肝炎防治指南 Chinese
4、 Hepatology,Dec 2005,Vol 10,No.4：348357Keeffe EB,el at.,July 2006;Clinical Gastroenterology and Hepatology2006;4:936962美国消化协会乙肝治疗规范美国消化协会乙肝治疗规范-建议暂不治疗建议暂不治疗 ALT ALT 正常，肝活检正常，肝活检 Knodell HAI 4Knodell HAI 4-治疗治疗 ALT ALT异常，异常，HBV DNA 10HBV DNA 105 5拷贝拷贝/mL(HBeAg/mL(HBeAg阳性）阳性）ALT ALT异常，异常，HBV DNA 10HBV
5、 DNA 104 4拷贝拷贝/mL(HBeAg/mL(HBeAg阴性）阴性）ALT ALT正常，肝活检正常，肝活检 Knodell HAI Knodell HAI 4 4Some of the information without approval 6 Lok AS,McMahon BJ.Hepatology.2007;45:507-539.Some of the information without approval 7Yang et al.Chinese J Dig Dis.2002;3:150.Some of the information without approval 8分层：
6、ALT 0.5-1 x ULN,ALT 1-2 x ULNALT 2-6 x ULN,ALT 6 x ULNYuen MF et al.Gut 2005;54:1610随访月数随访月数并发症危险率并发症危险率 (%)(%)ALTALT与肝脏并发症与肝脏并发症u3,233 名中国慢性乙肝患者ALT 2-6 X ULNALT 1-2 X ULNALT 6 X ULN01020300306090120150180Some of the information without approval 9*Chen CJ,et al.,Risk of Hepatocellular Carcinoma Acro
7、ss a Biological Gradient of Serum Hepatitis B Virus DNA Level;JAMA 2006;295:6573基线人群特征：基线人群特征：HBeAg(-),ALT正常,进入研究时无肝硬化(n=2,925)HBV DNAHBV DNA10103 3 10104 4如何控制如何控制?.14.14.12.12.1.1.08.08.06.06.04.04.02.020 00 01 12 23 34 45 56 67 78 89 91010 1111 1212 1313HCCHCC累积发生率累积发生率随访时间（年）随访时间（年）基线基线HBV DNAHB
8、V DNA水平水平10610104 410105 510103 310104 430030010103 3300300106104105103104300103300Some of the information without approval 10Some of the information without approval 11从而改善生活质量和延从而改善生活质量和延长存活时间长存活时间1.Liaw Y-F,et al.J Gastroenterol Hepatol.2005;25:472-89.2.慢性乙型肝炎防治指南 Chinese Hepatology,Dec 2005,Vol
9、10,No.4：3483573.Lok A.Viral Hepatitis Summit.24-26 August 2006,Cleveland,Ohio,USASome of the information without approval 12持续的持续的HBV DNA抑制抑制ALT防止肝病进展防止肝病进展为肝硬化、肝衰竭为肝硬化、肝衰竭或肝癌或肝癌减少死亡减少死亡或进行肝移植或进行肝移植Keeffe EB,el at.,A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in th
10、e United States:An Update,16 July 2006;Clinical Gastroenterology and Hepatology2006;4:936962Some of the information without approval 13Some of the information without approval 14Some of the information without approval 15中国乙肝指南中国乙肝指南:干扰素疗程固定干扰素疗程固定 抗病毒药物抗病毒药物 HBeAg(+):1HBeAg(+):1年年 HBV DNAHBV DNA转阴、
11、转阴、ALTALT复常且发生复常且发生e e抗原血清转换后继续抗原血清转换后继续治疗治疗1212月（月（22年年 ）HBeAg(-):1HBeAg(-):1年年 HBV DNAHBV DNA转阴、转阴、ALTALT复常后继续治疗复常后继续治疗1818月月 （2.52.5年年 ）美国消化协会乙肝治疗规范美国消化协会乙肝治疗规范:抗病毒药物抗病毒药物 HBeAg(+):1HBeAg(+):1年年HBV DNAHBV DNA转阴、且发生转阴、且发生e e抗原血清转换后继续治疗抗原血清转换后继续治疗6-126-12月（月（1.51.5年年 ）HBeAg(-)HBeAg(-)：长期治疗：长期治疗慢性乙型
12、肝炎防治指南 Chinese Hepatology,Dec 2005,Vol 10,No.4：348357Keeffe EB,el at.,A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States:An Update,16 July 2006;Clinical Gastroenterology and Hepatology2006;4:936962Some of the information without approval 16疾病进展患者的比例疾
13、病进展患者的比例 月月安慰剂安慰剂 (n=215)(n=215)ITT 人群人群拉米夫定拉米夫定(n=436)(n=436)p=0.001安慰剂安慰剂P=0.00121%9%Liaw et al,N Engl J Med 2004,351:1521-1531.安慰剂安慰剂肝脏失代偿肝癌自发性细菌性腹膜炎出血食管静脉曲张肝病相关的死亡Some of the information without approval 17安慰剂安慰剂 (n=215)(n=215)拉米夫定拉米夫定 (n=436)(n=436)诊断诊断HCCHCC的比例的比例诊断时间（月）诊断时间（月）拉米夫定拉米夫定安慰剂安慰剂P=
14、0.047Liaw et al,N Engl J Med 2004,351:1521-1531.5%10%Some of the information without approval 18*Patients with child-Turcotte-Pugh A cirrhosisIncidence of HCCp105105 copies/ml(virologic breakthrough)HBV DNA 105 copies/ml(maintained virologic response)62154877231111025719287No.at riskSome of the info
15、rmation without approval 19Di Marco V et al.Antivir Ther.2005;10(3):431-9 Some of the information without approval 20Some of the information without approval 21Keeffe EB,el at.,A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States:An Update,16 July 2006
16、;Clinical Gastroenterology and Hepatology2006;4:936962Some of the information without approval 22Some of the information without approval 23Some of the information without approval 24Some of the information without approval 25Some of the information without approval 26Some of the information without approval 27Some of the information without approval 28Some of the information without approval 29Some of the information without approval 30Some of the information without approval 31Keeffe EB,el at.
